Business Wire

Veracode Delivers End-to-End Risk Coverage with New Tools: AI-Powered Dynamic Analysis Security Testing with External Attack Surface Management

23.4.2025 17:42:00 CEST | Business Wire | Press Release

Share

Veracode, a global leader in application risk management, today announced new capabilities to help organizations address emerging threats, giving security professionals better visibility and control in one place. The launch includes new AI-powered functionality in the Dynamic Application Security Testing (DAST)product and an External Attack Surface Management (EASM) capability. Together, they enable security teams to discover their entire attack surface and prioritize the most critical risk to streamline and simplify security scanning.

“Security teams need to see and secure everything; not only what is inside their perimeter,” said Derek Maki, Head of Product at Veracode. “With our latest DAST capabilities and Application Risk Management platform enhancements, we’re helping organizations shift from vulnerability scanning to holistic risk management, to better identify risk residing in unidentified external assets.”

Tackling Risk Across a Growing Attack Surface

Modern development cycles and cloud adoption mean organizations are grappling with a rapidly expanding attack surface. According to the 2024 Verizon Data Breach Investigations Report, web applications remain a primary target for cyberattacks, accounting for nearly half of all incidents. Moreover, Veracode’s latest software security research found an alarming increase in the average fix time for flaws once discovered, with organizations taking three months—or 47 percent— longer than five years ago.

Veracode’s latest innovations address these critical challenges head on by offering frictionless integration for comprehensive risk management, faster remediation, and intuitive scans with real-time results. Organizations can more effectively balance the speed of modern development with software security.

Automated Discovery, Risk-based Prioritization, and Real-time Reporting

Veracode EASM capabilities automate external attack surface discovery by identifying and continuously monitoring potential entry points for bad actors. The product automatically tracks internet-exposed systems and services, including APIs, web apps, mobile applications, and cloud-based assets—many of which are often unknown or unmanaged. With automated discovery, EASM uncovers blind spots and delivers:

  • Complete Visibility: Consistent identification and monitoring of all external assets to reduce visibility gaps.
  • Risk-Based Prioritization: Streamlined focus on the most critical threats to minimize points of entry for an attacker.
  • Seamless Security Integration: With a connector to Veracode Risk Manager (VRM) planned for later this year, static (SAST), software composition (SCA), and dynamic analysis findings are prioritized and contextualised in one place, giving a holistic view of risk and control.

Maki said, “In today’s threat landscape, organizations must contend with an unprecedented number of potential entry points,” Maki explained. “Veracode EASM provides security teams with the attacker’s perspective and delivers the capability to continuously identify, analyze, and mitigate risks before exploitation can occur.”

Veracode’s new Enterprise Mode for DAST Essentials is a significant advancement in dynamic application security testing. Leveraging the capability, security teams can more easily prioritize and remediate critical vulnerabilities in web applications and APIs.

With features designed to accommodate large-scale, complex application portfolios, key capabilities include:

  • Advanced crawling and auditing for deep, highly customizable, and accurate scanning
  • AI-Assisted auto-login to reduce authentication failures and easily implement the DAST program across the organization
  • Internal Scan Management (ISM) for scanning behind corporate firewalls
  • A Streamlined, intuitive interface for faster, simpler setup and configuration
  • Real-time flaw reporting and a panoramic view of risk across projects

"DAST Enterprise Mode empowers security teams to work faster, smarter, and safer,” noted Maki. “With real-time analysis in a unified platform, it eliminates the challenge of fragmented tools and enables mature, resilient risk management with centralized visibility and control.”

Experience the Tools Live at RSAC 2025

Veracode will showcase its latest capabilities at RSAC Conference in San Francisco (April 28 - May 1, 2025). Visit booth #1243 for interactive demos and expert discussions on how to stay ahead of emerging threats and improve security posture.

Learn more about Veracode’s products on the website.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform offers adaptive software security and is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, Malicious Package Detection, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

Copyright © 2025 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250423385599/en/

Contacts

For more information:
Katy Gwilliam
kgwilliam@veracode.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye